Vascular Disease Discovery Protocol
Launched by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) · May 25, 2018
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
The Vascular Disease Discovery Protocol is a clinical trial designed to study heart and blood vessel diseases, especially those linked to genetic factors. Researchers want to gather information from individuals who have these conditions, their family members, and healthy volunteers. This study aims to better understand how genetic mutations and predispositions can affect vascular health, which is crucial since heart and blood diseases are the leading causes of death and disability in the U.S.
To participate, individuals aged 2 and older who may have a genetic heart or blood vessel disease, as well as their relatives and healthy volunteers, are welcome. Participants will go through a series of tests and evaluations, which may include medical history reviews, physical exams, and various imaging tests. They might also provide samples of blood, urine, or saliva. Each participant’s experience will vary, with some visits lasting just a few hours while others may take longer. Overall, this trial is a step towards better understanding and possibly improving the treatment of vascular diseases.
Gender
ALL
Eligibility criteria
- * INCLUSION CRITERIA:
- • All subjects must be between the ages of 2-100 years old.
- • Affected pregnant women if they have been referred with a known or suspected pathology or if they become pregnant while on study.
- • Unaffected related pregnant women (including spouses/partners) for cord blood and tissue collection (surgical waste) only at the time of delivery.
- EXCLUSION CRITERIA:
- • Healthy volunteers unable to give informed consent
- • Healthy volunteers who decline to have blood drawn and/or tissue studies or who do not consent to have samples stored for future research.
- • Cognitively impaired individuals who are not affected.
- • Cognitively impaired individuals not related to affected subjects.
About National Heart, Lung, And Blood Institute (Nhlbi)
The National Heart, Lung, and Blood Institute (NHLBI) is a leading component of the National Institutes of Health (NIH), dedicated to advancing research and clinical trials focused on cardiovascular, pulmonary, and hematologic diseases. With a mission to improve public health through innovative research, the NHLBI supports a wide range of studies aimed at understanding, preventing, and treating heart and lung conditions. By collaborating with academic institutions, healthcare providers, and patient communities, the NHLBI strives to translate scientific discoveries into effective clinical practices, ultimately enhancing the quality of life for individuals affected by these critical health issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bethesda, Maryland, United States
Patients applied
Trial Officials
Manfred Boehm, M.D.
Principal Investigator
National Heart, Lung, and Blood Institute (NHLBI)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials